77956-39-9

Usage

InChI:InChI=1/C11H11NO2/c1-12-8-6-10(13)9-4-2-3-5-11(9)14-7-8/h2-6,12H,7H2,1H3

Upstream product

• 62557-53-3 2,3,4,5-tetrahydro-1-benzoxepine-3,5-dione 
• 74-89-5 methylamine 
• 77956-92-4 methyl 2-(2-acetylphenoxy)acetate 

Downstream Products

• 102220-65-5 3-methylamino-3,4-dihydro-1-benzoxepine-5-(2H)-one 
• 77956-93-5 cis-3-methylamino-2,3,4,5-tetrahydro-1-benzoxepine-5-ol 
• 77956-93-5 trans-3-methylamino-2,3,4,5-tetrahydro-1-benzoxepine-5-ol 
• 102220-86-0 (3S,5R)-3-Dimethylamino-2,3,4,5-tetrahydro-benzo[b]oxepin-5-ol; compound with toluene-4-sulfonic acid 
• 102220-86-0 (3R,5R)-3-Dimethylamino-2,3,4,5-tetrahydro-benzo[b]oxepin-5-ol; compound with toluene-4-sulfonic acid 

Relevant academic research and scientific papers

Synthesis of 3-amino-2,3,4,5-tetrahydro-1-benzoxepine-5-ols and their action on gastric motility

3-Amino-2,3,4,5-tetrahydro-1-benzoxepine-5-ols are synthesized by condensation of 2,3,4,5-tetrahydro-1-benzoxepine-3,5-diones with amines and subsequent one or two step reduction. The pharmacological action of these compounds on the gastric motility of anesthetized rats is described. The effects both after parenteral and after enteral application were determined using a pressure recording technique. Dose response curves of KC 2450 (rac. cis-3-methylamino-2,3,4,5-tetrahydro-1-benzoxepine-5-ol hydrochloride; prop. INN for the base: exepanol) and of domperidone are given.

1-Benzoxepin-5 (2H)-one derivatives and pharmaceutical compositions

Novel, 3-amino-1-benzoxepin-5 (2H)-one derivatives and methods for their production are disclosed. These derivatives correspond to the Formula I: STR1 wherein: R1 and R2 independently of one another are hydrogen, C1 -C5 alkyl, C1 -C5 alkyl substituted with a terminal phenyl, or a phenyl containing one or two halogens, methyl or methoxy groups, a 3,4-methylenedioxy or a 3,4-ethylenedioxy group, C2 -C5 alkyl substituted with terminal hydroxy or methoxy or, C3 -C4 alkenyl; or one of R1 and R2 are hydrogen or a C1 -C5 alkyl and the other is a C2 -C5 alkyl substituted with a terminal NR5 R6 ; R5 and R6 independently of one another are hydrogen or C1 -C5 alkyl; or R5 and R6 are together a 5 to 7 member ring, or R5 and R6 are together a 5 to 7 member ring having heterogeneous oxygen, sulfur or nitrogen; R1 and R2 are together a 5 to 7 member ring, or R1 and R2 are together a 5 to 7 member ring having heterogeneous oxygen, sulfur or NR7 ; R7 is hydrogen, methyl, benzyl or phenyl; R3 and R4 independently of one another are hydrogen, halogen, C1 -C4 alkyl, C1 -C4 alkoxy or C1 -C4 alkylthio; or one of R3 and R4 is trifluoromethyl or nitro and the other is hydrogen; and the acid addition salts thereof. These compounds have a favorable effect on the treatment of spasms of the stomach-intestinal tract and, therefore, constitute the active ingredient of pharmaceutical compositions and methods for the treatment of disorders of the stomach and intestinal tract. Processes for the preparation of the derivatives and their acid addition salts and intermediate products for their preparation are also descrived.